The global Gestational Trophoblastic Disease market size was valued at US$ 2148 million in 2024 and is forecast to a readjusted size of USD 2856 million by 2031 with a CAGR of 4.2% during review period.
Gestational trophoblastic disease (GTD) is听a group of rare diseases in which abnormal trophoblast cells grow inside the uterus after conception. In gestational trophoblastic disease (GTD), a tumor develops inside the uterus from tissue that forms after conception (the joining of sperm and egg).
The global gestational trophoblastic disease (GTD) market refers to the market for diagnostic tests, treatments, and management strategies aimed at addressing GTD, a group of rare tumors that arise in the cells of the placenta during pregnancy. GTD includes conditions such as hydatidiform mole, gestational trophoblastic neoplasia, and choriocarcinoma.
The market for GTD is driven by several factors, including the increasing incidence of these diseases, advancements in diagnostic techniques, and improvements in treatment options. Early detection and accurate diagnosis are crucial for effective management of GTD. Diagnostic methods include ultrasound, human chorionic gonadotropin (hCG) measurement, and histopathological examination.
The primary treatment for GTD is the surgical removal of the affected tissue, which is often followed by chemotherapy in cases of gestational trophoblastic neoplasia and choriocarcinoma. Methotrexate is commonly used as a chemotherapy drug, and other chemotherapeutic agents may also be employed depending on the stage and type of the disease. In cases of high-risk or resistant GTD, additional treatments such as radiation therapy may be recommended.
Geographically, North America and Europe hold a significant share in the global GTD market, primarily due to factors such as well-established healthcare infrastructure, advanced diagnostic technologies, and increased awareness about GTD. Asia-Pacific is also experiencing growth in the GTD market, attributed to factors such as rising healthcare expenditure, improving healthcare infrastructure, and increasing awareness about women鈥檚 health.
Key players in the global GTD market include pharmaceutical companies, diagnostic test manufacturers, and healthcare providers specializing in women鈥檚 health. These companies focus on developing innovative diagnostic tests, drugs, and treatment protocols to improve patient outcomes and ensure better management of GTD.
However, challenges in the GTD market include the rarity of these diseases, leading to limited awareness and expertise among healthcare professionals, as well as the potential for complications and the need for individualized treatment approaches. Additionally, the emotional and psychological impact of GTD on patients and their families is an area that requires attention and support.
In summary, the global gestational trophoblastic disease market is driven by factors such as the increasing incidence of these rare tumors, advancements in diagnostic techniques, and improvements in treatment options. North America and Europe currently lead the market, but Asia-Pacific is witnessing growth. Key players in the market continue to invest in research and development to improve diagnostic accuracy, develop targeted therapies, and ensure optimal management of GTD.
This report is a detailed and comprehensive analysis for global Gestational Trophoblastic Disease market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Gestational Trophoblastic Disease market size and forecasts, in consumption value ($ Million), 2020-2031
Global Gestational Trophoblastic Disease market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Gestational Trophoblastic Disease market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Gestational Trophoblastic Disease market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Gestational Trophoblastic Disease
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Gestational Trophoblastic Disease market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bristol Myers Squibb, Antares Pharma, Novartis AG, Accord Healthcare Limited, Eli Lilly and Company, Sanofi, Bayer AG, Amgen, Merck KGaA, Teva Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Gestational Trophoblastic Disease market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chemotherapy
Surgery
Radiation Therapy
Others
Market segment by Application
Hospitals
Clinics
Cancer Research Institutes
Others
Market segment by players, this report covers
Bristol Myers Squibb
Antares Pharma
Novartis AG
Accord Healthcare Limited
Eli Lilly and Company
Sanofi
Bayer AG
Amgen
Merck KGaA
Teva Pharmaceuticals
B.P Pharma
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Gestational Trophoblastic Disease product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Gestational Trophoblastic Disease, with revenue, gross margin, and global market share of Gestational Trophoblastic Disease from 2020 to 2025.
Chapter 3, the Gestational Trophoblastic Disease competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Gestational Trophoblastic Disease market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Gestational Trophoblastic Disease.
Chapter 13, to describe Gestational Trophoblastic Disease research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 Market Overview
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Gestational Trophoblastic Disease by Type
1.3.1 Overview: Global Gestational Trophoblastic Disease Market Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Gestational Trophoblastic Disease Consumption Value Market Share by Type in 2024
1.3.3 Chemotherapy
1.3.4 Surgery
1.3.5 Radiation Therapy
1.3.6 Others
1.4 Global Gestational Trophoblastic Disease Market by Application
1.4.1 Overview: Global Gestational Trophoblastic Disease Market Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Hospitals
1.4.3 Clinics
1.4.4 Cancer Research Institutes
1.4.5 Others
1.5 Global Gestational Trophoblastic Disease Market Size & Forecast
1.6 Global Gestational Trophoblastic Disease Market Size and Forecast by Region
1.6.1 Global Gestational Trophoblastic Disease Market Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Gestational Trophoblastic Disease Market Size by Region, (2020-2031)
1.6.3 North America Gestational Trophoblastic Disease Market Size and Prospect (2020-2031)
1.6.4 Europe Gestational Trophoblastic Disease Market Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Gestational Trophoblastic Disease Market Size and Prospect (2020-2031)
1.6.6 South America Gestational Trophoblastic Disease Market Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Gestational Trophoblastic Disease Market Size and Prospect (2020-2031)
2 Company Profiles
2.1 Bristol Myers Squibb
2.1.1 Bristol Myers Squibb Details
2.1.2 Bristol Myers Squibb Major Business
2.1.3 Bristol Myers Squibb Gestational Trophoblastic Disease Product and Solutions
2.1.4 Bristol Myers Squibb Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2020-2025)
2.1.5 Bristol Myers Squibb Recent Developments and Future Plans
2.2 Antares Pharma
2.2.1 Antares Pharma Details
2.2.2 Antares Pharma Major Business
2.2.3 Antares Pharma Gestational Trophoblastic Disease Product and Solutions
2.2.4 Antares Pharma Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2020-2025)
2.2.5 Antares Pharma Recent Developments and Future Plans
2.3 Novartis AG
2.3.1 Novartis AG Details
2.3.2 Novartis AG Major Business
2.3.3 Novartis AG Gestational Trophoblastic Disease Product and Solutions
2.3.4 Novartis AG Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2020-2025)
2.3.5 Novartis AG Recent Developments and Future Plans
2.4 Accord Healthcare Limited
2.4.1 Accord Healthcare Limited Details
2.4.2 Accord Healthcare Limited Major Business
2.4.3 Accord Healthcare Limited Gestational Trophoblastic Disease Product and Solutions
2.4.4 Accord Healthcare Limited Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2020-2025)
2.4.5 Accord Healthcare Limited Recent Developments and Future Plans
2.5 Eli Lilly and Company
2.5.1 Eli Lilly and Company Details
2.5.2 Eli Lilly and Company Major Business
2.5.3 Eli Lilly and Company Gestational Trophoblastic Disease Product and Solutions
2.5.4 Eli Lilly and Company Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2020-2025)
2.5.5 Eli Lilly and Company Recent Developments and Future Plans
2.6 Sanofi
2.6.1 Sanofi Details
2.6.2 Sanofi Major Business
2.6.3 Sanofi Gestational Trophoblastic Disease Product and Solutions
2.6.4 Sanofi Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2020-2025)
2.6.5 Sanofi Recent Developments and Future Plans
2.7 Bayer AG
2.7.1 Bayer AG Details
2.7.2 Bayer AG Major Business
2.7.3 Bayer AG Gestational Trophoblastic Disease Product and Solutions
2.7.4 Bayer AG Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2020-2025)
2.7.5 Bayer AG Recent Developments and Future Plans
2.8 Amgen
2.8.1 Amgen Details
2.8.2 Amgen Major Business
2.8.3 Amgen Gestational Trophoblastic Disease Product and Solutions
2.8.4 Amgen Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2020-2025)
2.8.5 Amgen Recent Developments and Future Plans
2.9 Merck KGaA
2.9.1 Merck KGaA Details
2.9.2 Merck KGaA Major Business
2.9.3 Merck KGaA Gestational Trophoblastic Disease Product and Solutions
2.9.4 Merck KGaA Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2020-2025)
2.9.5 Merck KGaA Recent Developments and Future Plans
2.10 Teva Pharmaceuticals
2.10.1 Teva Pharmaceuticals Details
2.10.2 Teva Pharmaceuticals Major Business
2.10.3 Teva Pharmaceuticals Gestational Trophoblastic Disease Product and Solutions
2.10.4 Teva Pharmaceuticals Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2020-2025)
2.10.5 Teva Pharmaceuticals Recent Developments and Future Plans
2.11 B.P Pharma
2.11.1 B.P Pharma Details
2.11.2 B.P Pharma Major Business
2.11.3 B.P Pharma Gestational Trophoblastic Disease Product and Solutions
2.11.4 B.P Pharma Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2020-2025)
2.11.5 B.P Pharma Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Gestational Trophoblastic Disease Revenue and Share by Players (2020-2025)
3.2 Market Share Analysis (2024)
3.2.1 Market Share of Gestational Trophoblastic Disease by Company Revenue
3.2.2 Top 3 Gestational Trophoblastic Disease Players Market Share in 2024
3.2.3 Top 6 Gestational Trophoblastic Disease Players Market Share in 2024
3.3 Gestational Trophoblastic Disease Market: Overall Company Footprint Analysis
3.3.1 Gestational Trophoblastic Disease Market: Region Footprint
3.3.2 Gestational Trophoblastic Disease Market: Company Product Type Footprint
3.3.3 Gestational Trophoblastic Disease Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Gestational Trophoblastic Disease Consumption Value and Market Share by Type (2020-2025)
4.2 Global Gestational Trophoblastic Disease Market Forecast by Type (2026-2031)
5 Market Size Segment by Application
5.1 Global Gestational Trophoblastic Disease Consumption Value Market Share by Application (2020-2025)
5.2 Global Gestational Trophoblastic Disease Market Forecast by Application (2026-2031)
6 North America
6.1 North America Gestational Trophoblastic Disease Consumption Value by Type (2020-2031)
6.2 North America Gestational Trophoblastic Disease Market Size by Application (2020-2031)
6.3 North America Gestational Trophoblastic Disease Market Size by Country
6.3.1 North America Gestational Trophoblastic Disease Consumption Value by Country (2020-2031)
6.3.2 United States Gestational Trophoblastic Disease Market Size and Forecast (2020-2031)
6.3.3 Canada Gestational Trophoblastic Disease Market Size and Forecast (2020-2031)
6.3.4 Mexico Gestational Trophoblastic Disease Market Size and Forecast (2020-2031)
7 Europe
7.1 Europe Gestational Trophoblastic Disease Consumption Value by Type (2020-2031)
7.2 Europe Gestational Trophoblastic Disease Consumption Value by Application (2020-2031)
7.3 Europe Gestational Trophoblastic Disease Market Size by Country
7.3.1 Europe Gestational Trophoblastic Disease Consumption Value by Country (2020-2031)
7.3.2 Germany Gestational Trophoblastic Disease Market Size and Forecast (2020-2031)
7.3.3 France Gestational Trophoblastic Disease Market Size and Forecast (2020-2031)
7.3.4 United Kingdom Gestational Trophoblastic Disease Market Size and Forecast (2020-2031)
7.3.5 Russia Gestational Trophoblastic Disease Market Size and Forecast (2020-2031)
7.3.6 Italy Gestational Trophoblastic Disease Market Size and Forecast (2020-2031)
8 Asia-Pacific
8.1 Asia-Pacific Gestational Trophoblastic Disease Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Gestational Trophoblastic Disease Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Gestational Trophoblastic Disease Market Size by Region
8.3.1 Asia-Pacific Gestational Trophoblastic Disease Consumption Value by Region (2020-2031)
8.3.2 China Gestational Trophoblastic Disease Market Size and Forecast (2020-2031)
8.3.3 Japan Gestational Trophoblastic Disease Market Size and Forecast (2020-2031)
8.3.4 South Korea Gestational Trophoblastic Disease Market Size and Forecast (2020-2031)
8.3.5 India Gestational Trophoblastic Disease Market Size and Forecast (2020-2031)
8.3.6 Southeast Asia Gestational Trophoblastic Disease Market Size and Forecast (2020-2031)
8.3.7 Australia Gestational Trophoblastic Disease Market Size and Forecast (2020-2031)
9 South America
9.1 South America Gestational Trophoblastic Disease Consumption Value by Type (2020-2031)
9.2 South America Gestational Trophoblastic Disease Consumption Value by Application (2020-2031)
9.3 South America Gestational Trophoblastic Disease Market Size by Country
9.3.1 South America Gestational Trophoblastic Disease Consumption Value by Country (2020-2031)
9.3.2 Brazil Gestational Trophoblastic Disease Market Size and Forecast (2020-2031)
9.3.3 Argentina Gestational Trophoblastic Disease Market Size and Forecast (2020-2031)
10 Middle East & Africa
10.1 Middle East & Africa Gestational Trophoblastic Disease Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Gestational Trophoblastic Disease Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Gestational Trophoblastic Disease Market Size by Country
10.3.1 Middle East & Africa Gestational Trophoblastic Disease Consumption Value by Country (2020-2031)
10.3.2 Turkey Gestational Trophoblastic Disease Market Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Gestational Trophoblastic Disease Market Size and Forecast (2020-2031)
10.3.4 UAE Gestational Trophoblastic Disease Market Size and Forecast (2020-2031)
11 Market Dynamics
11.1 Gestational Trophoblastic Disease Market Drivers
11.2 Gestational Trophoblastic Disease Market Restraints
11.3 Gestational Trophoblastic Disease Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Gestational Trophoblastic Disease Industry Chain
12.2 Gestational Trophoblastic Disease Upstream Analysis
12.3 Gestational Trophoblastic Disease Midstream Analysis
12.4 Gestational Trophoblastic Disease Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Bristol Myers Squibb
Antares Pharma
Novartis AG
Accord Healthcare Limited
Eli Lilly and Company
Sanofi
Bayer AG
Amgen
Merck KGaA
Teva Pharmaceuticals
B.P Pharma
听
听
*If Applicable.
